Reinfection of Transplanted Livers in HCV- and HCV/HIV-Infected Patients Is Characterized by a Different MicroRNA Expression Profile.
HCV
HCV/HIV
NGS
liver transplantation
miRNA
Journal
Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052
Informations de publication
Date de publication:
16 02 2022
16 02 2022
Historique:
received:
26
12
2021
revised:
11
02
2022
accepted:
13
02
2022
entrez:
25
2
2022
pubmed:
26
2
2022
medline:
9
4
2022
Statut:
epublish
Résumé
After liver transplantation, HCV/HIV co-infected patients present, compared to the HCV mono-infected ones, increased HCV viral load, rapid progression to liver fibrosis and higher mortality. Liver biopsies (LB), obtained routinely 6 months after transplantation, represent a unique model to assess the early events related to graft re-infection. Here, we used miRNA sequencing of LB obtained from both HCV-and HCV/HIV-infected recipients, to identify transcriptional profiles able to explain the more severe outcome of these latter. miRNAs of 3 healthy livers, 3 HCV-LB and 3 HCV/HIV-LB were sequenced by Illumina HiSeq2500 platform. The DIANA-miRPath v3.0 webserver and DIANA-microT-CDS algorithm (v5.0) were used to characterize the functions of differentially expressed (DE-) miRNAs, querying the KEGG and Gene Ontology-Biological Process databases. LB obtained from infected patients were characterized, with respect to controls, by a miRNA profile related to viral infection, immune system signaling and DNA damage in HCV-induced carcinogenesis. Instead, HCV-LB and HCV/HIV-LB differed in the expression of miRNAs involved in immunological and apoptotic processes and in extracellular matrix remodeling. liver reinfection processes are associated with early miRNA changes. Further studies are necessary to establish their prognostic role and possible actionability.
Sections du résumé
BACKGROUND
After liver transplantation, HCV/HIV co-infected patients present, compared to the HCV mono-infected ones, increased HCV viral load, rapid progression to liver fibrosis and higher mortality. Liver biopsies (LB), obtained routinely 6 months after transplantation, represent a unique model to assess the early events related to graft re-infection. Here, we used miRNA sequencing of LB obtained from both HCV-and HCV/HIV-infected recipients, to identify transcriptional profiles able to explain the more severe outcome of these latter.
METHODS
miRNAs of 3 healthy livers, 3 HCV-LB and 3 HCV/HIV-LB were sequenced by Illumina HiSeq2500 platform. The DIANA-miRPath v3.0 webserver and DIANA-microT-CDS algorithm (v5.0) were used to characterize the functions of differentially expressed (DE-) miRNAs, querying the KEGG and Gene Ontology-Biological Process databases.
RESULTS
LB obtained from infected patients were characterized, with respect to controls, by a miRNA profile related to viral infection, immune system signaling and DNA damage in HCV-induced carcinogenesis. Instead, HCV-LB and HCV/HIV-LB differed in the expression of miRNAs involved in immunological and apoptotic processes and in extracellular matrix remodeling.
CONCLUSIONS
liver reinfection processes are associated with early miRNA changes. Further studies are necessary to establish their prognostic role and possible actionability.
Identifiants
pubmed: 35203343
pii: cells11040690
doi: 10.3390/cells11040690
pmc: PMC8869900
pii:
doi:
Substances chimiques
MicroRNAs
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
Nucleic Acids Res. 2015 Jul 1;43(W1):W460-6
pubmed: 25977294
Eur J Clin Microbiol Infect Dis. 1995 Nov;14(11):949-53
pubmed: 8654444
Viruses. 2020 Jun 28;12(7):
pubmed: 32605316
Int J Oncol. 2021 May;58(5):
pubmed: 33760107
J Med Virol. 2021 Aug;93(8):4992-5000
pubmed: 33818800
Lancet. 2014 Jul 19;384(9939):241-8
pubmed: 25042234
Hepatology. 2011 Jan;53(1):209-18
pubmed: 20890893
Cell Rep. 2017 Oct 3;21(1):141-153
pubmed: 28978468
J Nephrol. 2020 Feb;33(1):157-165
pubmed: 31359371
Transplant Direct. 2021 Jun 08;7(7):e707
pubmed: 34124343
Methods Mol Biol. 2011;724:259-67
pubmed: 21370018
PLoS Negl Trop Dis. 2014 Aug 14;8(8):e3088
pubmed: 25122182
World J Gastroenterol. 2014 May 14;20(18):5353-62
pubmed: 24833865
Gut. 2012 Nov;61(11):1600-9
pubmed: 22267590
Front Physiol. 2018 Oct 01;9:1394
pubmed: 30327618
J Mol Med (Berl). 2016 Mar;94(3):311-20
pubmed: 26489607
Eur Biophys J. 2017 Dec;46(8):813-820
pubmed: 28866771
World J Gastroenterol. 2014 Aug 28;20(32):11095-115
pubmed: 25170198
Genome Biol. 2014;15(12):550
pubmed: 25516281
Ann Hepatol. 2017 Aug 1;16(4):514-520
pubmed: 28611268
Proc Natl Acad Sci U S A. 2010 Jan 5;107(1):264-9
pubmed: 20018759
Front Immunol. 2014 Sep 25;5:461
pubmed: 25309543
Inflamm Res. 2017 Jun;66(6):477-486
pubmed: 28285394
Curr HIV Res. 2021;19(1):27-34
pubmed: 32900348
Oncol Lett. 2016 Oct;12(4):2567-2573
pubmed: 27698829
Oncol Rep. 2017 Jul;38(1):393-401
pubmed: 28560434
Open Forum Infect Dis. 2020 Apr 02;7(5):ofaa115
pubmed: 32391403
J Hepatol. 1995 Jun;22(6):696-9
pubmed: 7560864
Int J Mol Sci. 2016 Feb 24;17(3):280
pubmed: 26927063
J Viral Hepat. 2013 Mar;20(3):158-66
pubmed: 23383654
Front Immunol. 2017 Feb 16;8:56
pubmed: 28261196
Part Fibre Toxicol. 2017 Aug 24;14(1):32
pubmed: 28899404
Br Med Bull. 2018 Sep 1;127(1):55-68
pubmed: 29868901
Virol Sin. 2017 Dec;32(6):503-510
pubmed: 29076011
Cancer Cell Int. 2017 Nov 17;17:104
pubmed: 29176935
Gastroenterology. 2019 Jun;156(8):2313-2329.e7
pubmed: 30836093
Front Immunol. 2021 Jun 22;12:624753
pubmed: 34239515
Transplantation. 2016 Jan;100(1):141-6
pubmed: 26177090
Sci Rep. 2016 Jan 28;6:19946
pubmed: 26818210
Ann Transplant. 2017 Nov 24;22:701-706
pubmed: 29170365
Cell Biosci. 2017 Jul 4;7:34
pubmed: 28680559
PLoS Med. 2020 May 14;17(5):e1003101
pubmed: 32407386
Virus Res. 2021 Apr 15;296:198336
pubmed: 33577860
Top Antivir Med. 2017 Feb/Mar;25(1):3-6
pubmed: 28402927
J Gen Virol. 2019 Mar;100(3):350-366
pubmed: 30702421
Clin Cancer Res. 2010 Feb 1;16(3):867-75
pubmed: 20103675
Nat Med. 2007 Nov;13(11):1324-32
pubmed: 17952090
Sci Rep. 2018 May 8;8(1):7227
pubmed: 29740045
Front Immunol. 2021 Aug 23;12:723196
pubmed: 34497613
J Viral Hepat. 2011 Dec;18(12):852-60
pubmed: 21050341
Mol Ther Oncolytics. 2018 Dec 31;12:173-194
pubmed: 30788428
PLoS Genet. 2019 Jun 19;15(6):e1008181
pubmed: 31216276
AIDS. 2021 Jul 15;35(9):1355-1363
pubmed: 33813557
Nat Rev Mol Cell Biol. 2014 Aug;15(8):509-24
pubmed: 25027649
Gastroenterol Res Pract. 2012;2012:473925
pubmed: 22474436
World J Gastroenterol. 2015 Jul 28;21(28):8562-8
pubmed: 26229398
Curr Opin HIV AIDS. 2011 Nov;6(6):478-82
pubmed: 22001892
Onco Targets Ther. 2016 Mar 03;9:1123-33
pubmed: 27042104
J Acquir Immune Defic Syndr. 2019 Dec 15;82(5):514-522
pubmed: 31714431
Viruses. 2012 Oct 26;4(11):2485-513
pubmed: 23202492
J Immunol. 2017 Jul 1;199(1):224-232
pubmed: 28533442
Transpl Int. 2019 Oct;32(10):1044-1052
pubmed: 31050044
World J Gastroenterol. 2021 Aug 7;27(29):4846-4861
pubmed: 34447230
Clin Liver Dis. 2017 May;21(2):289-301
pubmed: 28364814
Int J Mol Sci. 2019 Sep 27;20(19):
pubmed: 31569791
AIDS. 2019 Feb 1;33(2):163-184
pubmed: 29547440
Front Immunol. 2021 Aug 12;12:726419
pubmed: 34456931
Front Neurosci. 2020 Jun 18;14:564
pubmed: 32625049
Nucleic Acids Res. 2011 Jan;39(Database issue):D152-7
pubmed: 21037258
PLoS One. 2018 Jun 6;13(6):e0197544
pubmed: 29874250
Mol Ther. 2020 May 6;28(5):1359-1372
pubmed: 32222157
Oncol Rep. 2017 Aug;38(2):652-664
pubmed: 28627640
Front Med (Lausanne). 2021 Feb 01;8:615342
pubmed: 33598470